Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)

NICE is unable to make a recommendation on nogapendekin alfa inbakicept (Anktiva) with Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, that is unresponsive to BCG in adults. This is because the company did not provide an evidence submission.

Last reviewed: 04 June 2026

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance